From the Department of Neuroradiology (R.D., H.A.Q., D.K., S.A., M.W.) and Department of Imaging Physics (P.S., B.A.T., P.H., H.-L.L.), The University of Texas MD Anderson Cancer Center
Auto-generated profile, based on publicly available information
Diana Kaya
From the Department of Neuroradiology (R.D., H.A.Q., D.K., S.A., M.W.) and Department of Imaging Physics (P.S., B.A.T., P.H., H.-L.L.), The University of Texas MD Anderson Cancer Center
Dynamic susceptibility contrast (DSC) MRI is widely used to assess relative cerebral blood volume (rCBV) in brain tumors using gadolinium-based contrast agents. Gadopiclenol, recently FDA-approved for use at half dose due to its high relaxivity, offers a potential strategy to reduce overall gadolinium exposure. This retrospective study evaluated DSC MRI performance with 0.05 mmol/kg gadopiclenol compared with standard-dose (0.10 mmol/kg) gadobutrol. 20 patients with brain tumors underwent gadopiclenol-based DSC MRI on 3T scanners and were compared with 20 matched controls receiving gadobutrol. Analysis of normal-appearing thalamic, frontal cortical gray matter, and white matter regions showed that gadopiclenol produced DSC time curves with shapes similar to gadobutrol, though with significantly smaller signal decreases and approximately half the peak ΔR2* values, consistent with dose scaling. Importantly, normalized rCBV values did not differ significantly between contrast agents in gray matter regions. These findings support the use of half-dose gadopiclenol for reliable rCBV assessment while reducing gadolinium exposure.
12 December 2024 in American Journal of Neuroradiology
SUMMARY: High-grade gliomas are the most frequent primary brain tumors, yet extraneural metastasis is exceedingly rare. This is in part secondary to the relatively poor survival of these patients and likely the shielding effect of the blood-brain barrier. Given the rarity of extraneural metastasis, the pathophysiology and imaging appearance of extraneural metastasis is under-reported and poorly understood. In this case series we present 6 patients with pathology-confirmed high-grade glioma and extraneural head and neck metastasis. We highlight imaging features of metastasis on CT, MRI, and PET/CT. We also explore potential correlations and pathophysiology of high-grade glioma metastasis to the head and neck region.
Imaging Findings of Distinct Molecular Subgroups of Medulloblastoma: All Fingers of the Palm are not the Same Purpose: WHO 2016 classification of brain tumors integrates 4 molecular defined subgroups of medulloblastoma: Wingless (WNT-activated), Sonic Hedgehog (SHH-activated) and TP53-mutant; Group 3 and Group 4. Each subgroup is characterized by specific molecular features, age